Published data suggest that the average concentration of busulfan at steady state (Bu Css) is critical for successful engraftment in children receiving busulfan as a conditioning agent for bone marrow transplantation (BMT). We previously found in children that a Bu Css Ͻ600 ng/ml correlated with autologous recovery/mixed chimerism; there was no correlation between Bu Css and regimen-related toxicity (RRT). In a cohort continuous with the previous trial, we prospectively evaluated targeted busulfan concentrations in 32 pediatric patients (age 0.6-18.5 years) with AML (n = 6), CML (n = 6) and non-malignant disorders (n = 20) receiving HLA-closely matched donor grafts. In this trial, individual busulfan pharmacokinetics were performed prior to admission. Busulfan doses were then adjusted to achieve a Bu Css target range of 600-900 ng/ml ± 10% depending on donor source and disease. A repeat study was done following dose 1 of the conditioning regimen. Thirty of thirty-two (94%) patients achieved target concentrations. Total busulfan doses ranged from 10.9 to 29 mg/kg. Thirty of thirty-two patients (94%) have durably engrafted. Grade 3/4 RRT occurred in seven patients (21%). Targeting Bu Css ranges of 600-900 ng/ml significantly improved our rate of successful engraftment from 74% to 94% (P = 0.043). These results indicate that targeted busulfan dosing optimizes allogeneic engraftment in children. Bone Marrow Transplantation (2001) 28, 1013-1018.
for malignant and non-malignant diseases. The attraction of the combination has been in the replacement of total body irradiation (TBI) with busulfan to avoid the difficulty of administering TBI and radiation-induced toxicities. The standard BMT dose of busulfan for both adults and children is 1 mg/kg administered orally every 6 h for 16 doses. However, the pharmacokinetics of high-dose busulfan are age-dependent, with children having lower plasma levels when compared to adults following the administration of a fixed mg/kg dose. [1] [2] [3] [4] Published data involving both children and adults suggest that there is a threshold necessary to achieve successful engraftment and minimize toxicity. 5, 6 We recently reported results from 31 children receiving total busulfan doses ranging from 14 to 20 mg/kg in which a Bu Css Ͻ600 ng/ml significantly correlated with autologous recovery/mixed chimerism (P = 0.018) ( Table 1 ). There were no graft failures in patients with Bu Css Ͼ600 ng/ml. We found no correlation between Bu Css and regimen related toxicity (RRT). 7 Based on these results, we sought to target a Bu Css range to maximize the rate of successful engraftment in children.
Materials and methods

Patients and treatments
In a cohort continuous with the previously published trial, we prospectively evaluated targeted busulfan levels in 39 pediatric patients (age 0.6-18.5 years) with AML/ALL (n = 9), CML (n = 7) and non-malignant diseases (n = 23) who were receiving HLA-matched or closely matched sibling (n = 22) or unrelated (n = 17) donor marrow grafts. Donor cell dose was maintained at approximately 5 × 10 8 per kg for all patients. Patient demographics are shown in Table 2 . All patients enrolled in BMT protocols from April 1996 to January 2000 which included busulfan as a conditioning agent, were eligible. One patient was excluded from analysis due to an adverse drug reaction to cyclophosphamide requiring a change in protocol. Six patients received an additional alkylating agent (thiotepa = 3; Child's weight adjusted for obesity melphalan = 3) and were excluded from analysis. Informed consent was obtained from the parents of all patients for participation in this study which was approved by the Committee on Human Research at the University of California, San Francisco. Patients over 12 years of age also provided consent to participate. Busulfan was administered as part of the BMT preparative regimen as the standard 16-dose, 4-day regimen beginning at 9 a.m. on the first day of conditioning. The total busulfan dose ranged from 10.9 to 28.9 mg/kg. Busulfan was followed by cyclophosphamide administered i.v. as 50 mg/kg on 4 consecutive days (n = 21) or 60 mg/kg on 2 consecutive days; 21/32 patients received a total dose of 80-90 mg/kg ATG; three patients received VP-16 (Table 2) . A compounded suspension of oral busulfan was administered through a nasogastric tube in children unable to reliably swallow tablets. All other patients received doses as 2 mg commercially available tablets. Patients were nil by mouth for at least 1 h before and after busulfan administration. All patients received phenytoin as prophylaxis for busulfan-related seizures beginning on the day of admission. Phenytoin levels were adjusted as needed to maintain therapeutic levels and prophylaxis was discontinued 24 to 48 h after the last dose of busulfan. In an attempt to decrease the risk of veno-occlusive disease (VOD) all patients also received low-dose heparin as a continuous infusion until 30 days after BMT.
Samples and pharmacokinetic analysis
Five days prior to admission for BMT, patients received a 0.5 mg/kg test dose of busulfan. Pharmacokinetic analysis was used to calculate a target dose to achieve a Bu Css range of 600-900 ng/ml ± 10% depending on the disease and donor source. All children were dosed to achieve a minimum Bu Css of 600 ng/ml ± 10%. For children with disease states (eg CML, Hurler's disease) or donor sources (eg MUD) felt to place them at high risk of graft failure, Bu Css target ranges were increased to 600-900 ng/ml ± 10%. Blood samples were obtained following dose 1 to confirm accuracy of the calculated dose. If further dosing adjustments were necessary, samples were obtained following doses 5, 9 and/or 13. Blood samples for the test dose and dose 1 were collected for analysis in heparinized tubes at time 30, 60, 120, 180, 240, 300 and 360 min; a 15-min sample was collected for children receiving busulfan as a suspension. For doses 5, 9 and 13, samples were collected at time 0, 30 (suspension only), 60, 120, 240 and 360 min. Samples were stored on ice until the plasma was separated and then frozen at −20°C until analysis. Specimens were sent on dry ice by overnight express mail for analysis by gas chromotography/mass spectometry at the Fred Hutchinson Cancer Research Center (FHCRC). 8 Pharmacokinetic information was available in time to adjust the 3 p.m. dose on the next day. Bu Css was calculated as previously described. 7 In patients requiring further dose adjustment, the Bu Css was calculated using average dosing (the cumulative dose divided by 16) and average clearance. Data reported for Bu Css are the mean value for each patient.
Toxicity and rejection
Regimen-related toxicity (RRT) was evaluated using BMT criteria described by Bearman et al 9 during the first 28 days post transplant and assigned a grade of 1 to 4. Engraftment was defined as an ANC Ͼ500 for 3 consecutive days with evidence of donor cells either by PCR for non-HLA DNA polymorphisms and/or in situ hybridization for X and Y chromosomes in sex-mismatched transplants. A quantitative estimate of engraftment (percent donor cells) was proBone Marrow Transplantation vided for sex-mismatched transplants. For non-HLA DNA assays, unique donor and recipient alleles were identified to assess full donor chimerism (sensitivity of 1-5%). For analysis, we included as 'engrafted' only those patients with 100% donor chimerism. Primary graft rejection was defined as no evidence of donor cells; secondary rejection was documented by initial evidence of donor engraftment followed by full autologous recovery. Engraftment was evaluated at 3-month intervals up to 1 year post BMT.
Statistical analysis
Fisher's exact test was used to evaluate whether achieving specific Bu Css can improve engraftment and to determine if there was a correlation between Bu Css and RRT. Engraftment rate and incidence of RRT were compared to that observed in our previously reported patients receiving standard-dose busulfan. 7 
Results
Busulfan concentration and graft rejection
Durable engraftment was achieved in 30/32 evaluable patients (94%); there were two patients with autologous recovery, one of which remained a mixed chimera (UPN 290). Using Fisher's exact test, engraftment was statistically superior (P = 0.043) in the targeted patients compared to previous non-targeted data. We evaluated the effect of ATG or CY dose and outcome. No correlation was detected, perhaps due to a high engraftment rate. Thirty of 32 (94%) patients achieved the desired target Bu Css concentrations ± 10% (Table 3) ; 8/32 (25%) patients achieved target levels of 600-900 ng/ml ± 10% with busulfan doses of 16 mg/kg ± 5%. Test doses were administered in 31/32 patients. Due to logistics involving availability of a matched unrelated marrow, one patient did not receive a test dose. In this patient, targeting was based upon dose 1 on the first day of conditioning; the patient required one dose adjustment with a resultant increase in dose to reach the target range. In the patients receiving test doses, no dose adjustments were required in 17/31 (55%) patients; nine (29%) and five (16%) patients required one and two dose adjustments, respectively. Of the 14 patients receiving a test dose and requiring dose adjustments, four patients required 1  270  898  600-900  1  1  Mucosa  1  275  566  600  0  2  Mucosa  1  281  576  600  1  0  none  1  283  840  600-900  2  2  Liver  1  287  593  600  0  1  Mucosa  1  290  618  600  0  1  Mucosa  0  294  583  600  0  3  Kidney/Liver  1  300  776  600  0  2  Mucosa  1  302  636  600  0  2  Mucosa  1  303  1130  600  2  2  Liver  1  304  587  600  2  2  Mucosa  1  308  859  900  0  2  Mucosa/Liver  1  312  860  900  1  2  Mucosa  1  317  927  900  1  2  Mucosa/Liver  1  328  798  800-900  1  3  CNS  1  329  616  600-700  1  1  Liver  1  342  928  900-950  2  3  Bladder/Liver  1  355  931  900  0  3  Bladder  1  358  936  900  0  2  Bladder/Liver  1  360  668  600  0  1  Mucosa  1  365  799  800  0  0  None  0  371  889  600-900  0  2  Renal/Mucosa  1  372  672  600  2  3  Liver/Kidney  1  375  689  600  0  1  Mucosa  1  376  939  900  1  2  Mucosa  1  377  648  600  1  1  Mucosa  1  378  620  600  1  2  Mucosa  1 UPN = unique patient number; Bu = busulfan; RRT = regimen-related toxicity; CNS = central nervous system. a 1 = engrafted; 0 = not engrafted.
dose increases, nine required dose decreases and one patient required both a dose increase and a dose decrease to reach the target range.
Busulfan concentration and toxicity
A toxicity analysis was completed in the 32 evaluable patients (Table 4) . There was a non-significant trend toward higher RRT with increasing Bu Css using Fisher's exact test. No correlation was found between CY dose and RRT. Compared to previous non-targeted patients, the incidence of grade 3 or 4 RRT increased from 16% to 21%.
Discussion
In our previous trial we found evidence indicating that busulfan has a narrow therapeutic index (600-900 ng/ml) when used as a conditioning agent for BMT in children. 7 The next step was to target busulfan ranges in an effort to improve engraftment and minimize toxicity. Achieving a target range is challenging due to the well-documented interpatient and intrapatient variability in busulfan clearance. This variability is in part caused by the fact that young children have a higher busulfan clearance when compared to adults Table 4 Regimen-related toxicity and older children. 2, 10, 11 These factors make it difficult for children to achieve desired blood concentrations when busulfan is administered as a standardized mg/kg dose. Therefore, we believe that therapeutic drug monitoring and target dose adjustment of busulfan is justified.
The benefits of targeting busulfan concentrations in children undergoing BMT remains controversial because data have yet to define the therapeutic range that will optimize outcome. 7 Slattery et al 5 found increased graft rejection with Bu Css levels Ͻ200 ng/ml in HLA-matched sibling grafts and Ͻ600 ng/ml in HLA-partially matched or unrelated donors. We previously found that children receiving closely matched (sibling, parent, unrelated donor) grafts with Bu Css Ͻ600 ng/ml had an increased incidence of autologous recovery. Our current study confirms that target ranges of Bu Css can be achieved and that a targeted Bu Css range of 600-900 ng/ml ± 10% in children correlates with increased engraftment.
The use of other alkylating agents in place of high-dose cyclophosphamide may influence the relationships between Bu Css and outcome or toxicity. 12, 13 Therefore, patients receiving melphalan or thiotepa in combination with low-dose cyclophosphamide were excluded from statistical analysis. VP-16 was added to the conditioning regimen of the three patients with familial hemophagocytic lymphohistiocytosis (FEL) in an attempt to eliminate residual disease rather than to increase myelosuppression or effect circulating lymphocytes. Since VP-16 has little immunosuppressive activity, we did not exclude these patients from our analysis.
The children in this clinical trial and the historical control group represent a continuous cohort of patients admitted to our facility over a 9-year time period. While it is ideal to conduct a controlled randomized trial, rapidly advancing information and technology make it unlikely that this can be accomplished in children receiving BMT.
Currently, there appears to be no way to predict which patients require individualized dosing. Some children may achieve desired target concentrations with standard-dose busulfan. We observed a tremendous scope of dosing, as low as 10.9 mg/kg and as high as 28.9 mg/kg to achieve a target Bu Css range of 600-900 ng/ml ± 10%. Non-standard dosing was necessary in 74% of our patients to achieve target Bu Css ranges. This is consistent with the report by Chattergoon et al 14 indicating that 67% of pediatric patients required dose adjustments to achieve target Bu Css. Ultimately, 94% of our children achieved the desired target Bu Css range.
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While some studies have found a relationship between Bu Css Ͼ900 ng/ml and RRT, 5, 15, 16 adults with CML appear to tolerate higher concentrations. 6 In our study, only seven patients had Bu Css levels Ͼ900 ng/ml; five of these patients had CML. This may have influenced the fact that we did not observe a significant trend towards higher RRT with increasing Bu Css. Perhaps due to a small sample size and high engraftment rates, we also found no significant decrease in RRT with lower doses of CY (120 vs 200 mg/kg).
In conclusion, there are few clinical trials of busulfan pharmacokinetics specifically in children. This study finds that achieving a target Bu Css range of 600-900 ng/ml ± 10% in children correlates with increased engraftment (94%), while the incidence of RRT does not. The implication of this study is that high engraftment rates in children are possible with targeted busulfan dosing. Targeting may in fact, reduce the risk of non-engraftment in this population by 75%.
